Navigation Links
Ikaria(R) Strengthens Research & Development Team
Date:7/1/2008

Appoints Dr. Deborah Petrowsky Vice President of Medical Affairs and Dr.

Steven Knapp Vice President of Regulatory Affairs

CLINTON, N.J., July 1 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced today the addition of two executives to its Research & Development division. Deborah Petrowsky, M.D., F.C.C.P. was named Vice President for Medical Affairs and Steven Knapp, M.S., Pharm.D. was appointed Vice President of Regulatory Affairs. Both will report directly to Ralf Rosskamp, M.D., Executive Vice President for Research and Development of Ikaria.

Dr. Rosskamp commented, "Deborah and Steven are valuable additions to our R&D team. Deborah brings with her extensive clinical experience in the critical care setting and a deep understanding of the crucial role of Medical Affairs in developing and maintaining relationships with our most influential customers. In addition, she has forged strong professional relationships in the Pulmonary and Endocrine Community and worked closely with the clinical teams on sponsor-initiated Phase 3b/4 studies.

"Steven has a proven track-record of successful interactions with regulatory authorities worldwide and has been an accomplished team player on many company project teams and inter-company alliance teams. He has significant expertise in regulatory due-diligence activities, which will help us to identify promising in-licensing candidates for Ikaria. I look forward to working with both Deborah and Steven as we continue to move our development pipeline forward."

Daniel Tasse, President & CEO of Ikaria, remarked, "Because we have a deep, very active product pipeline, it is vital that we have strong Medical and Regulatory Affairs teams in place. Deborah and Steve bring a wealth of experience in their respective areas of expertise to the R&D team, and we are very pleased that they have elected to join Ikaria. I am certain that they will provide strong leadership as we endeavor to expand the indications for INOmax, progress our clinical pipeline, and capitalize on Ikaria's mission to develop novel treatments for the critically ill in the in-hospital and ICU setting."

Dr. Petrowsky was previously World Wide Medical Director, Medical Affairs at Pfizer in New York, where she was responsible for the medical approval of all product promotional materials, marketing and sales, as well as publication strategies for the brands Exubera, Revatio (a drug for pulmonary hypertension) and Chantix. Prior to joining Pfizer, she practiced as a Pulmonary/Critical Care Specialist in both hospital and private practice. Dr. Petrowsky received her MD from UMDNJ -- New Jersey Medical School and is Board Certified in Internal Medicine, Pulmonary Disease and Critical Care. She completed a Fellowship in Pulmonary and Critical Care Medicine at the Hahnemann Division of Allegheny University Hospital in Philadelphia, PA.

Dr. Knapp brings over 20 years of regulatory experience in all phases of drugs, biologics, diagnostics, devices and cosmetics. He most recently was the Vice President of Global Regulatory Affairs of Par Pharmaceuticals, Branded Division, and prior to that he spent 13 years at Bristol-Myers-Squibb, where his most recently held position was Executive Director, Global Regulatory Strategy. Previously, he held positions of increasing importance at Schering- Plough. Dr. Knapp began his career as Product Development Scientist at Johnson & Johnson Research, Janssen Pharmaceuticals. He holds a M.S. in Pharmaceutical Engineering from Rutgers College of Pharmacy and Engineering and a Pharm.D. from Rutgers College of Pharmacy.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceutical and biological products and drug/device combinations for the critically ill in the hospital and ICU setting. The company's product, INOmax(R) (nitric oxide) for inhalation, is an FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns. The drug also is approved by regulatory authorities and used in Canada, Europe, Australia and Latin America. In addition to the ongoing clinical development as well as the marketing and selling of its INOmax product, Ikaria is engaged in a number of Phase 2 trials with Covox(R) (carbon monoxide) for inhalation and Phase 1 trials with hydrogen sulfide (H2S) for various critical care indications. Ikaria has a staff of approximately 350 people and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen, LA. For more information on Ikaria, please visit http://www.ikaria.com.

CONTACTS

Matthew Bennett

Ikaria

(908) 238-6673

matthew.bennett@ikaria.com

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kenyan malaria success strengthens call for free insecticide-treated nets for all
2. International study strengthens case for daily calcium pill
3. Wachovia Strengthens Its Healthcare Industry Receivables and Cash Management Capabilities
4. Essilor Strengthens its Polarized Lens Distribution Network With the Acquisition of KBco
5. Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy
6. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
7. Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy
8. Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008
9. Start Licensing, Inc. Further Strengthens Position in Cloning Industry With New Patents
10. Scientx USA Strengthens Leadership Team With Appointment of Bryce IntVeld as Vice President of Sales
11. Dowden Custom Media Strengthens e-Media
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... 2017 , ... Pivot Point Consulting, a ... the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of ... clients with initial vendor selection and pre-implementation planning through go-live support and post-live ...
(Date:8/22/2017)... ... , ... Nurses at Apple Rehab Watch Hill , a nursing and ... certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... for Medicare and Medicaid Services, to have a CPI machine that will provide better ...
(Date:8/22/2017)... ... ... “Wilderness Voices”: a collection of poetry inspired by life on a Kentucky ... published author, Martha McKown, an ordained United Methodist minister with graduate degrees in Religious ... her older sisters studied High School literature. She loved the early English folk ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
(Date:8/2/2017)... 2017  Life Flight Network and PeaceHealth Oregon Network announced ... care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Life Flight Network work collaboratively to move patients who require ... a time sensitive emergency exists. ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology: